Catalyst, Isu Abxis To Develop Hemophilia B Candidate

Oct 9 2013

Catalyst Biosciences has formed a strategic collaboration with South Korean biologics manufacturing and development company Isu Abxis to develop Catalyst's next-generation Factor IX development candidate FIX-NG (CB 2679d) for the prevention and treatment of bleeding in hemophilia B patients. The collaboration will advance FIX-NG through IND-enabling preclinical studies, manufacturing, and the completion of Phase I studies.

Per the agreement, Isu Abxis will advance FIX-NG through preclinical and Phase I studies, and Catalyst and Isu will collaborate and share in profits on the development and commercialization of FIX-NG worldwide. Isu will pay Catalyst an up-front licensing fee and milestone payments through the end of the Phase I trial and holds an option to exclusively commercialize FIX-NG in Korea. Catalyst retains development and commercial ownership rights of the program outside of Korea.

"Catalyst has significant experience in the development of next-generation coagulation factors including FVIIa, FIX, and FXa, while Isu has the biologics manufacturing expertise to make complex proteins from research through commercialization," said Nassim Usman, Ph.D., Catalyst's CEO, in a statement. "We believe that the collaboration with Isu Abxis will accelerate FIX-NG's development and ultimately provide improved therapy for hemophilia B patients."

This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.